Ambalal Sarabhai Enterprises share price
NSE: AMBALALSABSE: 500009Pharmaceuticals & BiotechnologySmall Cap
Ambalal Sarabhai Enterprises Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 1981
Last close ₹35.31down ₹0.22 (0.62%)BSE ₹35.00
Share price at the NSE close on 29 Oct 2026. Previous close ₹35.53.
29 Oct: open ₹34.75, high ₹35.95, low ₹34.56
52-week range of BSE trades to 29 Oct 2026
₹23.12Low, 28 Jan 2026₹49.98High, 20 Aug 2026
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Next results date: the board meets on 5 Nov 2026 to consider: quarterly results. Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹271 Cr2,324th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 19.96
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.71
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 9.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 5.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.33
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 3,556
Results
Standalone, as consolidated accounts are on record for only 8 of the last ten years; ₹ crore.Ambalal Sarabhai Enterprises quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +4.9%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +5.8%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹0.54 Crdown 64.19%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹0.03 Crdown 98.86%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 5.5%
Revenue by quarter
Peak revenue ₹1.73 Cr, quarter to Mar 2025; lowest ₹0.00 Cr, quarter to Sep 2024
Net profit by quarter, a loss in red
- Net profit
- Loss
A loss in 2 of the 8 quarters shown
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 1.17 | 1.73 | 1.64 | 0.79 | 0.00 | 1.52 | 0.54 |
| Net profit | 4.31 | 8.43 | −4.96 | 6.88 | −0.38 | 1.84 | 2.65 | 0.03 |
| Net margin | – | 722.3% | −287.0% | 420.8% | −48.5% | – | 174.6% | 5.5% |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹3.94 Crdown 2.37%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹11 Crup 33.36%
- Net margin
- 278.7%
Revenue by year
Peak revenue ₹4.04 Cr, year to Mar 2025; lowest ₹0.00 Cr, year to Mar 2020
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 4 of the 10 years shown
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.5 | 0.9 | – | 0.0 | 0.0 | 0.1 | 3.7 | 3.8 | 4.0 | 3.9 |
| Net profit | −21.5 | −1.4 | −3.9 | 15.6 | −9.4 | 3.0 | 4.1 | 2.6 | 8.2 | 11.0 |
| Net margin | −1,424.9% | −155.6% | – | – | – | 2,318.5% | 110.9% | 67.8% | 204.0% | 278.7% |
Standalone. Years to March. The latest is shaded.
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- PharmaceuticalsPharmaceuticals, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹111 Crup 1.91%54.6%
- ElectronicsElectronics, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹92 Crup 4.59%45.4%
The pill is the change in revenue on the year before; the share is of all the businesses together.
Valuation
Today, against the company's own history. Dividend yield is not shown: no dividend in the years on record.Ambalal Sarabhai Enterprises PE ratio and valuation
Price to earnings
At or below today's level on 63% of 1,106 trading days over the last 5 years.
LowestHighest
Its median14.06Industry median28.38
Price to book
At or below today's level on 17% of 1,952 trading days since Nov 2018.
LowestHighest
Its median2.60Industry median2.99
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −30.8% | +32.4% | −47.7% | 0.0% |
| 3 years | +5.8% | +38.4% | −23.5% | 0.0% |
| 5 years | +6.6% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 3 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the year to Mar 2023.
Mutual fund holdings
2 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before.
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 2
| Fund | |||
|---|---|---|---|
 Motilal Oswal BSE Healthcare ETFMotilal Oswal Mutual Fund | 1,409 | 0.01% | ₹56,000 |
 Bandhan BSE Healthcare Index FundBandhan Mutual Fund | 664 | 0.01% | ₹26,000 |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 30 Oct 2025.Ambalal Sarabhai Enterprises insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Others3 purchases, 0 sales₹1.00 CrNo saleNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.₹1.00 Cr
- Promoters and promoter group: no market trade · 1 off-market move
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Ambalal Sarabhai Enterprises competitors and peers
Pharmaceuticals, 215 listed companies, priced on 29 Oct 2026. The table lists the 8 companies closest to Ambalal Sarabhai Enterprises in market cap. 1 company in the table last traded before then: its row is priced on its last trade.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Aarey Drugs & PharmaceuticalsAAREYDRUGS | 353 | – | – | −7.7% | – | – | 1.8% | 0.00% |
 Astonea LabsASTONEALAB | 340 | 75.19 | 5.94 | – | – | 12.0% | – | 0.00% |
 Astal LaboratoriesASTALLTD | 276 | 28.38 | 0.83 | +122.7% | +4.4% | 5.4% | 4.2% | 0.00% |
 Lyka LabsLYKALABS | 276 | – | 2.98 | −2.6% | – | −9.2% | −8.0% | 0.00% |
 Everest OrganicsEVERESTO | 241 | 45.84 | 3.19 | +5.5% | −15.2% | 7.2% | 10.5% | 0.00% |
 Zenotech LaboratoriesZENOTECH | 232 | – | 2.51 | −9.4% | – | −4.5% | −8.8% | 0.00% |
 BDH IndustriesBDH | 230 | 19.68 | 2.99 | +44.8% | +22.9% | 16.1% | 18.2% | 1.25% |
 Gennex LaboratoriesGENNEX | 218 | 11.85 | 0.98 | +24.1% | +7.3% | 9.0% | 7.0% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Ambalal Sarabhai Enterprises announcements
Oct 2026
28 Oct · Board meeting
Meeting on 5 Nov 2026: quarterly results
Aug 2026
13 Aug · Submission Of Quarterly Snapshots
Ambalal Sarabhai Enterprises annual report, year to Mar 2026
Ambalal Sarabhai Enterprises share price by year
Each calendar year to 2025.Ambalal Sarabhai Enterprises share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025BSE close | 28.58 | −46.7% | 57.48 | 26.39 |
| 2024BSE close | 53.58 | +40.9% | 72.49 | 39.92 |
| 2023BSE close | 38.02 | +41.3% | 47.02 | 20.51 |
| 2022BSE close | 26.90 | −20.1% | 45.00 | 25.95 |
| 2021BSE close | 33.65 | +66.2% | 63.80 | 17.40 |
| 2020BSE close | 20.25 | +29.1% | 29.50 | 12.60 |
| 2019BSE close | 15.69 | +18.5% | 18.95 | 9.20 |
| 2018BSE close | 13.24 | +27.8% | 16.47 | 9.51 |
| 2017BSE close | 10.36 | +43.1% | 14.68 | 7.09 |
| 2016BSE close | 7.24 | −6.6% | 10.98 | 4.58 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 28 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 28 Oct 2026 | 34.89 | 35.85 | 34.89 | 35.53 | 35.29 | 17,843 |
| 27 Oct 2026 | 34.21 | 35.94 | 34.00 | 34.91 | 34.88 | 62,146 |
| 26 Oct 2026 | 34.65 | 35.99 | 33.50 | 35.56 | 35.14 | 28,686 |
| 23 Oct 2026 | 36.50 | 36.50 | 34.62 | 34.65 | 35.13 | 46,405 |
| 22 Oct 2026 | 36.10 | 37.00 | 36.10 | 36.44 | 36.58 | 22,737 |
| 21 Oct 2026 | 38.98 | 38.98 | 36.59 | 36.65 | 37.06 | 32,710 |
| 19 Oct 2026 | 38.20 | 39.00 | 37.65 | 38.51 | 38.62 | 50,348 |
| 16 Oct 2026 | 37.80 | 38.35 | 36.51 | 37.79 | 37.42 | 38,651 |
| 15 Oct 2026 | 38.80 | 39.09 | 37.10 | 37.85 | 37.70 | 19,688 |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- AMBALALSA
- BSE code
- 500009
- ISIN
- INE432A01017
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.ase.life
- CIN
- L52100GJ1978PLC003159
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1978
- Registered office
- Shanti Sadan, Mirzapur Road, Ahmedabad 380001, Gujarat
- Share registrar
- MCS Share Transfer Agent Ltd
- Keeps the register of shareholders and handles transfers and dividend payments